New ACP Obesity Guidelines: GLP-1 Drugs Take the Lead

Obesity remains a major global health challenge that requires robust and modern clinical strategies. Consequently, the American College of Physicians recently released the updated ACP obesity guidelines to assist outpatient clinicians. These evidence-based recommendations establish a clear therapeutic hierarchy for weight management in nonpregnant adults. Furthermore, they combine pharmacologic interventions with essential lifestyle modifications to optimize patient outcomes.

First-Line Recommendations Under the ACP Obesity Guidelines

For nonpregnant adults with a body mass index of 30 or higher, the guideline prioritizes specific medications. Specifically, clinicians should initiate either semaglutide or tirzepatide as co-equal first-line pharmacologic treatments. These newer incretin-based therapies produce significant and sustained weight reduction compared to older options. However, clinicians must always pair these pharmaceutical agents with lifestyle modifications like nutrition counseling and physical activity. Therefore, this combined approach addresses the chronic nature of obesity more effectively.

Alternative Drug Options and Hierarchy

When first-line options are unavailable or unsuitable, clinicians can consider alternative therapies. Under this framework, phentermine-topiramate serves as the second-line treatment option. Subsequently, liraglutide represents the third-line choice for patients requiring weight management. Finally, the combination of naltrexone-bupropion functions as the fourth-line pharmacotherapy. Additionally, the guideline outlines a similar hierarchy for overweight patients with comorbidities. For individuals with a body mass index between 27 and 30 and comorbidities like diabetes, semaglutide and tirzepatide remain first-line choices. Meanwhile, liraglutide serves as the second-line option for this high-risk patient population.

Key Factors for Shared Decision-Making

Clinicians should not make the choice of medication automatically or without thorough patient discussion. Instead, they must engage in shared decision-making to evaluate individual benefits, harms, and costs. Furthermore, clinical comorbidities, accessibility, and patient preferences must guide the treatment selection. For example, phentermine-topiramate requires monthly pregnancy tests and is contraindicated in patients with cardiovascular disease. Moreover, clinicians must monitor patients for potential risks like suicidal ideation with naltrexone-bupropion. Consequently, careful patient selection ensures safety and treatment adherence.

Frequently Asked Questions

Q1: What are the first-line pharmacologic treatments recommended by the new guidelines?

The guidelines recommend semaglutide and tirzepatide as the first-line pharmacologic options for weight management. However, clinicians should always prescribe these medications alongside sustained lifestyle modifications.

Q2: Which comorbid conditions qualify overweight adults for these medications?

Adults with a body mass index between 27 and 30 qualify if they have specific risk factors. Specifically, these comorbidities include type 2 diabetes, dyslipidemia, hypertension, obstructive sleep apnea, or cardiovascular disease.

References

1. Qaseem A et al. Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026). Ann Intern Med. 2026 Jun 16. doi: 10.7326/ANNALS-25-02714. PMID: 42296496.
2. American College of Physicians. ACP issues new living clinical guideline on using medications to manage overweight and obesity. Annals of Internal Medicine. Published June 15, 2026.
3. American Journal of Managed Care (AJMC). ACP Names Semaglutide, Tirzepatide as First-Line Pharmacotherapy for Obesity. Published June 15, 2026.